Advanced

Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice

McMurray, J; Cohen-Solal, A; Dietz, R; Eichhorn, E; Erhardt, Leif RW LU ; Hobbs, FDR; Krum, H; Maggioni, A; McKelvie, RS and Pina, IL, et al. (2005) In European Journal of Heart Failure 7(5). p.710-721
Abstract
Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of pharmacological agents into clinical practice, thereby denying patients with heart failure (HF) the benefits of drug treatments proven to improve well-being and prolong life. This may be due to unfamiliarity with the evidence-base for these therapies, the clinical guidelines recommending the use of these treatments or both, as well as concerns regarding adverse events. ACE inhibitors have long been the cornerstone of therapy for systolic HF irrespective of aetiology. Recent trials have now shown that treatment with beta-blockers, aldosterone antagonists and angiotensin receptor blockers also leads... (More)
Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of pharmacological agents into clinical practice, thereby denying patients with heart failure (HF) the benefits of drug treatments proven to improve well-being and prolong life. This may be due to unfamiliarity with the evidence-base for these therapies, the clinical guidelines recommending the use of these treatments or both, as well as concerns regarding adverse events. ACE inhibitors have long been the cornerstone of therapy for systolic HF irrespective of aetiology. Recent trials have now shown that treatment with beta-blockers, aldosterone antagonists and angiotensin receptor blockers also leads to substantial improvements in outcome. In order to accelerate the safe uptake of these treatments and to ensure that all eligible patients receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of HE The objective of these recommendations is to provide practical guidance for non-specialists, in order to increase the use of evidenced based therapy for HF. These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
beta-blockers, clinical recommendations, digoxin, eplerenone, heart, failure, hydralazine, isosorbide dinitrate, pharmacology, treatment, spironolactone, angiotensin receptor blockers, ACE inhibitors, aldosterone antagonists
in
European Journal of Heart Failure
volume
7
issue
5
pages
710 - 721
publisher
Elsevier
external identifiers
  • wos:000236408500003
  • pmid:16087129
  • scopus:23744514591
ISSN
1879-0844
DOI
10.1016/j.ejheart.2005.07.002
language
English
LU publication?
yes
id
eed8dbe2-3218-4d91-8a1e-e5fb168a4005 (old id 893972)
date added to LUP
2008-01-16 14:51:57
date last changed
2017-09-17 04:49:00
@article{eed8dbe2-3218-4d91-8a1e-e5fb168a4005,
  abstract     = {Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of pharmacological agents into clinical practice, thereby denying patients with heart failure (HF) the benefits of drug treatments proven to improve well-being and prolong life. This may be due to unfamiliarity with the evidence-base for these therapies, the clinical guidelines recommending the use of these treatments or both, as well as concerns regarding adverse events. ACE inhibitors have long been the cornerstone of therapy for systolic HF irrespective of aetiology. Recent trials have now shown that treatment with beta-blockers, aldosterone antagonists and angiotensin receptor blockers also leads to substantial improvements in outcome. In order to accelerate the safe uptake of these treatments and to ensure that all eligible patients receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of HE The objective of these recommendations is to provide practical guidance for non-specialists, in order to increase the use of evidenced based therapy for HF. These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines.},
  author       = {McMurray, J and Cohen-Solal, A and Dietz, R and Eichhorn, E and Erhardt, Leif RW and Hobbs, FDR and Krum, H and Maggioni, A and McKelvie, RS and Pina, IL and Soler-Soler, J and Swedberg, K},
  issn         = {1879-0844},
  keyword      = {beta-blockers,clinical recommendations,digoxin,eplerenone,heart,failure,hydralazine,isosorbide dinitrate,pharmacology,treatment,spironolactone,angiotensin receptor blockers,ACE inhibitors,aldosterone antagonists},
  language     = {eng},
  number       = {5},
  pages        = {710--721},
  publisher    = {Elsevier},
  series       = {European Journal of Heart Failure},
  title        = {Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice},
  url          = {http://dx.doi.org/10.1016/j.ejheart.2005.07.002},
  volume       = {7},
  year         = {2005},
}